Clinical Trials Logo

Polycystic Ovary Syndrome clinical trials

View clinical trials related to Polycystic Ovary Syndrome.

Filter by:

NCT ID: NCT02429128 Completed - Clinical trials for Polycystic Ovary Syndrome (PCOS)

14 Weeks Exercise Training on Lean Women With and Without PCOS

Start date: July 2014
Phase: N/A
Study type: Interventional

The aim of this project is to investigate the pathophysiology of PCOS in regards to the metabolic profile including defects in insulin sensitivity in skeletal muscle and adipose tissue, and to investigate the effects of exercise training on these parameters.

NCT ID: NCT02419482 Completed - Clinical trials for Polycystic Ovary Syndrome

Improving Reproductive Function in Women With Polycystic Ovary Syndrome by High Intensity Interval Training

IMPROV-IT
Start date: June 2015
Phase: N/A
Study type: Interventional

The aim is to investigate whether 16 weeks of high intensity interval training, followed by 36 weeks of home-based exercise, will improve menstrual frequency in women with Polycystic Ovary Syndrome (PCOS) compared with a non-exercising control group.

NCT ID: NCT02409914 Completed - Insulin Resistance Clinical Trials

Brain Metabolism in Polycystic Ovary Syndrome

Start date: March 2010
Phase:
Study type: Observational

The purpose of this study is to investigate whether higher insulin resistance in young women with Polycystic ovary syndrome (PCOS) is associated with reduced cerebral metabolic rate of glucose (CMRglu). Brain volumes using magnetic resonance imaging (MRI) and quantitative cerebral glucose uptake using dynamic positron emission tomography (PET) were obtained.

NCT ID: NCT02389088 Completed - Clinical trials for Polycystic Ovary Syndrome

Effect of Increased Circulating Androgens on Granulosa Cell Responses to FSH.

Start date: April 2006
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the effect of increased circulating androgens on estradiol production by the granulosa cells in response to FSH stimulus.

NCT ID: NCT02385396 Completed - Infertility Clinical Trials

Myo-inositol Therapy on the Dynamics of Embryo Development in Patients Suffering From PCOS Undergoing ICSI Treatment

Start date: n/a
Phase: Phase 2
Study type: Interventional

The purpose of this study is to analyse the activity of myo-inositol on pregnancy rate, embryo development dynamics and oestradiol and progesterone concentration in blood serum and Superoxide Dismutase (SOD) and catalase concentration in follicular fluid of patients with Polycystic Ovary Syndrome (PCOS) undergoing Intracytoplasmic Sperm Injection (ICSI).

NCT ID: NCT02381184 Completed - Infertility Clinical Trials

Extended Clomiphene Citrate Regimen in Women With Polycystic Ovary Syndrome

Start date: June 2014
Phase: Phase 2/Phase 3
Study type: Interventional

One hundred and thirty six anovulatory women with CC-resistant PCOS were scheduled randomly into two equal groups. Group A (n=68); received CC (100 mg/day from cycle day 3 for 10 days) for up to six cycles. Group B (n=68) underwent LOD and followed up for 6 months. The primary outcome was the ovulation rate in each group; secondary outcomes were midcycle endometrial thickness and serum estradiol, midluteal serum progesterone, and the rates of clinical pregnancy and abortion.

NCT ID: NCT02352597 Completed - Polycystic Ovaries Clinical Trials

Phytoestrogens as an Alternative to Estradiol in Ovulation Induction in PCOS

PCOS
Start date: January 2013
Phase: Phase 4
Study type: Interventional

Prospective study conducted on 150 women with polycystic ovarian syndrome (PCOS) were randomly divided into 3 groups: group I (50 women) received clomiphene citrate (CC) only 50 mg orally every 8 hours started from cycle day 3 for 5 days, group II (50 women) received 2mg estradiol valerate daily from cycle day 7 - 11 in addition to CC and group III (50 women) received phytoestrogen (20mg of cimifuga racemosa from day 1- 12) in addition to CC.

NCT ID: NCT02341703 Completed - Infertility Clinical Trials

Ovulation Induction in Clomiphene Citrate Resistant PCO Women

Start date: February 2015
Phase: Phase 0
Study type: Interventional

Polycystic ovary syndrome (PCOS) affects 5-10% of women in childbearing age. Hyperinsulinemia contributes to chronic anovulation commonly encountered in women with PCOS. The first choice therapy is clomiphene citrate (CC). In CC resistant cases, the American College of Obstetrics and Gynecology (ACOG) recommends the use of insulin sensitizer metformin. Other insulin sensitizing agents include rosiglitazone and pioglitazone. Pioglitazone is said to improve fertility and ovulation in patients with PCOS.CC may be associated with poor endometrial thickening due to its antiestrogenic effect. Letrozole may improve this condition. In this study we will compare the effect of combined letrozole-metformin with that of combined letrozole-pioglitazone in ovulation induction in CC-resistant PCOS women

NCT ID: NCT02328404 Completed - Clinical trials for Polycystic Ovary Syndrome

The Effect of Vitamin D Supplementation Among Overweight Jordanian Women With Polycystic Ovary Syndrome

Start date: February 2014
Phase: Phase 3
Study type: Interventional

The purpose of this study is to examine the effect of 50,000 IU vitamin D3 supplementation on Polycystic Ovary Syndrome prognosis. A randomized, double-blind, Parallel design comparing vitamin D with Placebo will be conducted on 60 overweight females diagnosed with PCOS according to Rotterdam criteria and have serum 25(OH)D level < 20 ng/ml. The results are expected to assess the improvement of Polycystic Ovary Syndrome prognosis and the effect of Vitamin D Supplementation on Chromium Serum Levels and Insulin Resistance.

NCT ID: NCT02304107 Completed - Infertility Clinical Trials

Comparison Between Letrozole and Urinary Purified FSH in Women With Clomiphene Citrate Resistant Polycystic Ovarian Syndrome.

FSH
Start date: May 2013
Phase: Phase 3
Study type: Interventional

210 women with clomiphene resistant PCOS will be randomly divided into 3 equal groups using computer generated random numbers. Group 1 will receive FSH, group 2 will have Letrozole and group 3 will act as the control group with no intervention.